Mylan Agrees to Pay $465 million in a Settlement for EpiPen Overcharges

Mylan, the makers of EpiPen, and federal investigators finalized a $465 million settlement of charge the drugmaker avoided paying state Medicaid programs higher rebates by improperly classifying the brand name drug as a generic medication. Read article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or


Leave a Reply